Annual CFO
$12.80 M
-$19.18 M-59.98%
31 December 2023
Summary:
Vanda Pharmaceuticals annual cash flow from operations is currently $12.80 million, with the most recent change of -$19.18 million (-59.98%) on 31 December 2023. During the last 3 years, it has fallen by -$38.97 million (-75.28%). VNDA annual CFO is now -92.44% below its all-time high of $169.34 million, reached on 31 December 2009.VNDA Cash From Operations Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Quarterly CFO
-$14.58 M
-$7.65 M-110.46%
30 September 2024
Summary:
Vanda Pharmaceuticals quarterly cash flow from operations is currently -$14.58 million, with the most recent change of -$7.65 million (-110.46%) on 30 September 2024. Over the past year, it has dropped by -$12.53 million (-611.27%). VNDA quarterly CFO is now -107.70% below its all-time high of $189.29 million, reached on 31 December 2009.VNDA Quarterly CFO Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
TTM CFO
-$17.67 M
-$12.53 M-243.75%
30 September 2024
Summary:
Vanda Pharmaceuticals TTM cash flow from operations is currently -$17.67 million, with the most recent change of -$12.53 million (-243.75%) on 30 September 2024. Over the past year, it has dropped by -$43.62 million (-168.10%). VNDA TTM CFO is now -109.63% below its all-time high of $183.49 million, reached on 30 September 2010.VNDA TTM CFO Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
VNDA Cash From Operations Performance
| PeriodPeriod | AnnualAnnual | QuarterlyQuarterly | TTMTTM |
|---|---|---|---|
| 1 y1 year | -60.0% | -611.3% | -168.1% |
| 3 y3 years | -75.3% | -255.2% | -131.1% |
| 5 y5 years | -57.3% | -343.1% | -134.4% |
VNDA Cash From Operations High & Low
| PeriodPeriod | Annual vs highAnnual vs high | Annual vs lowAnnual vs low | Quarter. vs highQuarter. vs high | Quarter. vs lowQuarter. vs low | TTM vs highTTM vs high | TTM vs lowTTM vs low | |
|---|---|---|---|---|---|---|---|
| 3 y | 3 years | -80.1% | at low | -145.8% | at low | -127.5% | at low |
| 5 y | 5 years | -80.1% | at low | -145.8% | at low | -127.5% | at low |
| alltime | all time | -92.4% | +115.7% | -107.7% | +60.2% | -109.6% | +78.7% |
Vanda Pharmaceuticals Cash From Operations History
| Date | Annual | Quarterly | TTM |
|---|---|---|---|
| Sept 2024 | - | -$14.58 M(+110.5%) | -$17.67 M(+243.7%) |
| June 2024 | - | -$6.93 M(-191.5%) | -$5.14 M(-55.0%) |
| Mar 2024 | - | $7.57 M(-302.8%) | -$11.43 M(-189.3%) |
| Dec 2023 | $12.80 M(-60.0%) | -$3.73 M(+82.0%) | $12.80 M(-50.7%) |
| Sept 2023 | - | -$2.05 M(-84.5%) | $25.95 M(-36.5%) |
| June 2023 | - | -$13.22 M(-141.6%) | $40.84 M(-31.6%) |
| Mar 2023 | - | $31.80 M(+237.8%) | $59.74 M(+86.8%) |
| Dec 2022 | $31.98 M(-50.2%) | $9.42 M(-26.6%) | $31.98 M(-35.0%) |
| Sept 2022 | - | $12.84 M(+125.8%) | $49.17 M(+7.5%) |
| June 2022 | - | $5.68 M(+40.5%) | $45.73 M(-22.6%) |
| Mar 2022 | - | $4.05 M(-84.8%) | $59.07 M(-8.0%) |
| Dec 2021 | $64.21 M(+24.0%) | $26.61 M(+183.1%) | $64.21 M(+12.8%) |
| Sept 2021 | - | $9.40 M(-50.6%) | $56.91 M(+0.0%) |
| June 2021 | - | $19.02 M(+106.9%) | $56.89 M(-8.1%) |
| Mar 2021 | - | $9.19 M(-52.4%) | $61.88 M(+19.5%) |
| Dec 2020 | $51.77 M(+12.7%) | $19.30 M(+105.9%) | $51.77 M(+22.5%) |
| Sept 2020 | - | $9.37 M(-61.0%) | $42.26 M(+8.7%) |
| June 2020 | - | $24.01 M(-2746.7%) | $38.89 M(+9.9%) |
| Mar 2020 | - | -$907.00 K(-109.3%) | $35.40 M(-23.0%) |
| Dec 2019 | $45.95 M(+53.2%) | $9.79 M(+63.2%) | $45.95 M(-10.6%) |
| Sept 2019 | - | $6.00 M(-70.8%) | $51.42 M(-5.0%) |
| June 2019 | - | $20.52 M(+112.7%) | $54.12 M(+42.4%) |
| Mar 2019 | - | $9.64 M(-36.8%) | $37.99 M(+26.7%) |
| Dec 2018 | $29.99 M(-1612.2%) | $15.26 M(+75.6%) | $29.99 M(+64.9%) |
| Sept 2018 | - | $8.69 M(+98.0%) | $18.19 M(+56.0%) |
| June 2018 | - | $4.39 M(+168.1%) | $11.66 M(+132.7%) |
| Mar 2018 | - | $1.64 M(-52.7%) | $5.01 M(-352.7%) |
| Dec 2017 | -$1.98 M(-75.5%) | $3.47 M(+59.9%) | -$1.98 M(-70.1%) |
| Sept 2017 | - | $2.17 M(-195.9%) | -$6.63 M(-12.3%) |
| June 2017 | - | -$2.26 M(-57.8%) | -$7.56 M(-11.7%) |
| Mar 2017 | - | -$5.36 M(+352.8%) | -$8.56 M(+5.7%) |
| Dec 2016 | -$8.10 M(-165.1%) | -$1.18 M(-195.3%) | -$8.10 M(+11.4%) |
| Sept 2016 | - | $1.24 M(-138.0%) | -$7.28 M(-45.6%) |
| June 2016 | - | -$3.26 M(-33.4%) | -$13.37 M(-770.1%) |
| Mar 2016 | - | -$4.90 M(+1276.1%) | $2.00 M(-84.0%) |
| Dec 2015 | $12.45 M(-115.3%) | -$356.00 K(-92.7%) | $12.45 M(-2242.7%) |
| Sept 2015 | - | -$4.85 M(-140.1%) | -$581.00 K(-82.5%) |
| June 2015 | - | $12.10 M(+117.8%) | -$3.33 M(-93.6%) |
| Mar 2015 | - | $5.55 M(-141.5%) | -$52.09 M(-36.1%) |
| Dec 2014 | -$81.55 M | -$13.39 M(+76.2%) | -$81.55 M(+1.5%) |
| Date | Annual | Quarterly | TTM |
|---|---|---|---|
| Sept 2014 | - | -$7.60 M(-79.3%) | -$80.32 M(-3.2%) |
| June 2014 | - | -$36.66 M(+53.4%) | -$82.99 M(+52.6%) |
| Mar 2014 | - | -$23.90 M(+96.7%) | -$54.37 M(+37.3%) |
| Dec 2013 | -$39.59 M(-11.9%) | -$12.15 M(+18.3%) | -$39.59 M(-4.1%) |
| Sept 2013 | - | -$10.27 M(+27.7%) | -$41.29 M(+0.3%) |
| June 2013 | - | -$8.04 M(-11.9%) | -$41.18 M(-9.2%) |
| Mar 2013 | - | -$9.13 M(-34.1%) | -$45.35 M(+1.0%) |
| Dec 2012 | -$44.92 M(+58.1%) | -$13.85 M(+36.3%) | -$44.92 M(+3.4%) |
| Sept 2012 | - | -$10.16 M(-16.8%) | -$43.42 M(+7.4%) |
| June 2012 | - | -$12.21 M(+40.6%) | -$40.43 M(+19.5%) |
| Mar 2012 | - | -$8.69 M(-29.7%) | -$33.84 M(+19.1%) |
| Dec 2011 | -$28.41 M(+160.7%) | -$12.36 M(+72.3%) | -$28.41 M(+34.3%) |
| Sept 2011 | - | -$7.17 M(+27.6%) | -$21.15 M(+11.0%) |
| June 2011 | - | -$5.62 M(+72.2%) | -$19.05 M(+104.1%) |
| Mar 2011 | - | -$3.26 M(-35.9%) | -$9.34 M(-14.3%) |
| Dec 2010 | -$10.90 M(-106.4%) | -$5.10 M(+0.4%) | -$10.90 M(-105.9%) |
| Sept 2010 | - | -$5.07 M(-223.8%) | $183.49 M(+2.0%) |
| June 2010 | - | $4.10 M(-184.9%) | $179.85 M(+6.9%) |
| Mar 2010 | - | -$4.83 M(-102.5%) | $168.30 M(-0.6%) |
| Dec 2009 | $169.34 M(-468.5%) | $189.29 M(-2272.2%) | $169.34 M(-766.5%) |
| Sept 2009 | - | -$8.71 M(+17.0%) | -$25.41 M(-15.3%) |
| June 2009 | - | -$7.45 M(+96.2%) | -$29.98 M(-10.9%) |
| Mar 2009 | - | -$3.79 M(-30.4%) | -$33.64 M(-26.8%) |
| Dec 2008 | -$45.96 M(-11.0%) | -$5.45 M(-59.0%) | -$45.96 M(-19.6%) |
| Sept 2008 | - | -$13.29 M(+19.6%) | -$57.13 M(+4.5%) |
| June 2008 | - | -$11.11 M(-31.0%) | -$54.65 M(+0.6%) |
| Mar 2008 | - | -$16.11 M(-3.1%) | -$54.35 M(+5.2%) |
| Dec 2007 | -$51.64 M(+0.0%) | -$16.62 M(+53.7%) | -$51.64 M(+11.9%) |
| Sept 2007 | - | -$10.82 M(+0.1%) | -$46.14 M(-11.7%) |
| June 2007 | - | -$10.80 M(-19.4%) | -$52.24 M(-3.8%) |
| Mar 2007 | - | -$13.41 M(+20.6%) | -$54.31 M(+5.2%) |
| Dec 2006 | -$51.62 M(+191.4%) | -$11.12 M(-34.3%) | -$51.62 M(+11.2%) |
| Sept 2006 | - | -$16.92 M(+31.6%) | -$46.40 M(+36.5%) |
| June 2006 | - | -$12.86 M(+20.0%) | -$34.01 M(+36.9%) |
| Mar 2006 | - | -$10.72 M(+81.6%) | -$24.84 M(+40.2%) |
| Dec 2005 | -$17.71 M(+105.6%) | -$5.90 M(+30.3%) | -$17.71 M(+50.0%) |
| Sept 2005 | - | -$4.53 M(+22.7%) | -$11.81 M(+62.1%) |
| June 2005 | - | -$3.69 M(+2.7%) | -$7.29 M(+102.7%) |
| Mar 2005 | - | -$3.59 M | -$3.59 M |
| Dec 2004 | -$8.61 M | - | - |
FAQ
- What is Vanda Pharmaceuticals annual cash flow from operations?
- What is the all time high annual CFO for Vanda Pharmaceuticals?
- What is Vanda Pharmaceuticals annual CFO year-on-year change?
- What is Vanda Pharmaceuticals quarterly cash flow from operations?
- What is the all time high quarterly CFO for Vanda Pharmaceuticals?
- What is Vanda Pharmaceuticals quarterly CFO year-on-year change?
- What is Vanda Pharmaceuticals TTM cash flow from operations?
- What is the all time high TTM CFO for Vanda Pharmaceuticals?
- What is Vanda Pharmaceuticals TTM CFO year-on-year change?
What is Vanda Pharmaceuticals annual cash flow from operations?
The current annual CFO of VNDA is $12.80 M
What is the all time high annual CFO for Vanda Pharmaceuticals?
Vanda Pharmaceuticals all-time high annual cash flow from operations is $169.34 M
What is Vanda Pharmaceuticals annual CFO year-on-year change?
Over the past year, VNDA annual cash flow from operations has changed by -$19.18 M (-59.98%)
What is Vanda Pharmaceuticals quarterly cash flow from operations?
The current quarterly CFO of VNDA is -$14.58 M
What is the all time high quarterly CFO for Vanda Pharmaceuticals?
Vanda Pharmaceuticals all-time high quarterly cash flow from operations is $189.29 M
What is Vanda Pharmaceuticals quarterly CFO year-on-year change?
Over the past year, VNDA quarterly cash flow from operations has changed by -$12.53 M (-611.27%)
What is Vanda Pharmaceuticals TTM cash flow from operations?
The current TTM CFO of VNDA is -$17.67 M
What is the all time high TTM CFO for Vanda Pharmaceuticals?
Vanda Pharmaceuticals all-time high TTM cash flow from operations is $183.49 M
What is Vanda Pharmaceuticals TTM CFO year-on-year change?
Over the past year, VNDA TTM cash flow from operations has changed by -$43.62 M (-168.10%)